943894--3/28/2008--EZENIA_INC

related topics
{product, liability, claim}
{product, market, service}
{customer, product, revenue}
{stock, price, share}
{personnel, key, retain}
{stock, price, operating}
{system, service, information}
{control, financial, internal}
Company Background and Evolution True Collaboration versus Videoconferencing We may be unable to sustain profitability A significant portion of our revenue is attributable to a small number of major customers- none of whom is obligated to continue to use our products and services. Loss of access to certain third-party technology utilized in our products could materially harm our business. Our success depends upon market acceptance of Internet-based collaboration products, in general, and our IWS product, in particular. If we are unable to adapt to the rapid pace of change in our market, our business could be adversely affected. Our results of operations would suffer if we are unable to effectively compete in the market for multimedia collaboration products. If we release products containing defects or experience delays in releasing new products, our competitive position could be adversely effected. The loss of our senior executives and key personnel or our failure to recruit talented directors, officers and personnel could harm our business. The trading price of our common stock may continue to be volatile, which may adversely affect our business, and investors in our common stock may experience substantial losses. Our common stock is traded on the OTC Bulletin Board, making it a more illiquid investment than if it were traded on a national securities exchange.

Full 10-K form ▸

related documents
943894--3/24/2009--EZENIA_INC
810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC
1006195--3/15/2007--MATRIXX_INITIATIVES_INC
943894--3/31/2010--EZENIA_INC
1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP
894237--6/29/2006--VISION_SCIENCES_INC_/DE/
718924--12/27/2006--SPAN_AMERICA_MEDICAL_SYSTEMS_INC
771252--3/8/2006--DIGITAL_ANGEL_CORP
780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC
1006045--3/30/2007--IRIDEX_CORP
882873--9/21/2009--UROLOGIX_INC
874734--3/8/2010--OSTEOTECH_INC
739944--3/11/2008--MEDTOX_SCIENTIFIC_INC
739944--3/15/2007--MEDTOX_SCIENTIFIC_INC
739944--3/17/2006--MEDTOX_SCIENTIFIC_INC
1270597--3/23/2007--MERISANT_CO
874716--2/27/2008--IDEXX_LABORATORIES_INC_/DE
834306--3/16/2006--BIOSITE_INC
1014507--6/1/2006--SCHICK_TECHNOLOGIES_INC
1050007--11/29/2007--NUTRACEUTICAL_INTERNATIONAL_CORP
10795--11/24/2010--BECTON_DICKINSON_&_CO
1013606--2/29/2008--ENDOLOGIX_INC_/DE/
1025573--4/2/2007--NATROL_INC
739944--3/10/2009--MEDTOX_SCIENTIFIC_INC
768408--6/24/2010--CYANOTECH_CORP
1006195--6/8/2009--MATRIXX_INITIATIVES_INC
882873--9/17/2010--UROLOGIX_INC
880432--9/28/2009--MISONIX_INC
1000736--3/2/2006--CAREMARK_RX_INC
862668--9/29/2008--ESCALON_MEDICAL_CORP